Substance / Medication

Fenbendazole

Overview

Active Ingredient
fenbendazole
RxNorm CUI
4325

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy of closantel against ivermectin- and fenbendazole-resistant Haemonchus sp. in sheep in Ontario, Canada.
Westers T, Jones-Bitton A, Menzies P et al. · Vet Parasitol · 2016
PMID: 27692328RCT
The efficacy of ivermectin, pyrantel and fenbendazole against Parascaris equorum infection in foals on farms in Australia.
Armstrong S K, Woodgate R G, Gough S et al. · Vet Parasitol · 2014
PMID: 25224788RCT
Safety of fenbendazole in Chinese ring-necked pheasants (Phasianus colchicus).
Griffith R, Yaeger M, Hostetter S et al. · Avian Dis · 2014
PMID: 24758107RCT
Use of fenbendazole-containing therapeutic diets for mice in experimental cancer therapy studies.
Duan Qiwen, Liu Yanfeng, Booth Carmen J et al. · J Am Assoc Lab Anim Sci · 2012
PMID: 22776123RCTFull text (PMC)
Efficacy of oxfendazole and fenbendazole against tortoise (Testudo hermanni) oxyurids.
Giannetto S, Brianti E, Poglayen G et al. · Parasitol Res · 2007
PMID: 17120044RCT
Macrocyclic lactone-resistant Parascaris equorum on stud farms in Canada and effectiveness of fenbendazole and pyrantel pamoate.
Slocombe J Owen D, de Gannes Rolph V G, Lake Mary C · Vet Parasitol · 2007
PMID: 16962243RCT
Comparative study on the selectivity of various spectrophotometric techniques for the determination of binary mixture of fenbendazole and rafoxanide.
Saad Ahmed S, Attia Ali K, Alaraki Manal S et al. · Spectrochim Acta A Mol Biomol Spectrosc · 2015
PMID: 26093118Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Fenbendazole (substance)
SNOMED CT
96134008
UMLS CUI
C0015821
RxNorm CUI
4325

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.